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A B S T R A C TObjective: Decision models are sometimes used alongside systematic
reviews to synthesize evidence. Clarity, however, is lacking about
when and how to conduct modeling studies in tandem with systema-
tic reviews, as well as about how to evaluate and present model
results. The objective of this study was to collect and analyze
information from various sources to inform the development of a
framework for deciding when and how a decision model should be
added to a systematic review. Methods: We collected data through
1) review and analysis of evidence reports that used decision models;
2) review and synthesis of current best practices for the development
of decision models; 3) interviews of Evidence-Based Practice Center
directors and selected staff, United States Preventive Services Task
Force members, and decision modelers who developed models used
by the United States Preventive Services Task Force; and 4) a focus
group of expert modelers. Results: Models are well suited to addresssee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.009
umn.edu.
ondence to: Franc-ois Sainfort, Division of Health
9, 420 Delaware Street, SE, Minneapolis, MN 5545gaps in the literature, better suited for certain types of research
questions, and essential for determining the value of information
relating to future research. Opinions differ regarding whether model
outputs constitute evidence, but interviewees expressed concern over
the lack of standards and directions in grading and reporting such
‘‘evidence.’’ Interviews of stakeholders and modelers revealed the
importance of communication and presentation of model results as
well as the importance of model literacy and involvement of stake-
holders. Conclusions: The study demonstrates the need for a frame-
work for deciding when and how to use models alongside systematic
reviews and provides information to develop such a framework.
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Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Systematic reviews are widely used to evaluate and synthesize
the scientific literature on a particular topic. Results from
systematic reviews are meant to help public and private organi-
zations develop guidelines and strategies that improve the
quality of health care and decision making. In the United States,
the Agency for Healthcare Research and Quality funds projects
through its Effective Health Care Program [1] to ‘‘Review and synthesize published and unpublished scientific
evidence. Generate new scientific evidence and analytic tools.
 Compile research findings that are synthesized and/or gener-
ated and translates them into useful formats for various
audiences.’’ [1]
Often, however, existing evidence cannot fully address the
relevant questions being asked. Decision models may enhancethe value of systematic reviews by adding a formal structure that
can be informed by, and also extrapolate beyond, the evidence to
produce additional outcomes relevant to decision makers. Since
the first application reported by Henschke and Flehinger [2] in 1967,
decision-analytic models have been increasingly used to evaluate
and compare competing public health and medical interventions.
While decision models may provide added value, the underlying
philosophical approach—creating additional knowledge through
modeling—is not necessarily congruent with the underlying phi-
losophical approach of systematic reviews —critical assessment
and evaluation of all research studies. At issue are the nature and
strength of the ‘‘evidence’’ generated by a model as opposed to the
nature and strength of evidence observed in a collection of studies
carefully screened and systematically evaluated. Historically, a
‘‘hierarchy of evidence’’ has been used that ranks randomized
clinical trials higher than other types of studies [3]. It is unclear
where decision models ‘‘fit’’ within this hierarchy.
Developing a decision model for a particular question requires
a synthesis of relevant literature pertaining to the natural historySociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Policy and Management, School of Public Health, University of
5, USA.
Table 1 – Summary of types of decision model
structures.
Model type General
description
Type of decision
best suited for
Decision tree Diagrams the risk
of events and
states of nature
over a fixed time
horizon
Interventions for
which the
relevant time
horizon is short
and fixed
Markov (cohort)
model
Simulates a
hypothetical
cohort of
individuals
through a set of
health states
over time
Modeling
interventions for
diseases or
conditions that
involve risk over
a long time
horizon and/or
recurrent events
Microsimulation
(individual)
model
Simulates one
individual at a
time; tracks the
past health
states of
individual and
models risk of
future events
stochastically
Modeling complex
disease
processes, when
Markov models
are too limiting
Dynamic model System of
differential
Modeling
interventions for
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 1 3 3 – 1 3 9134(or risk) of disease, effectiveness and risks of alternative interven-
tions, and health-related quality of life. Thus, modeling endeavors
rely on much of the same information provided by systematic
reviews. Models, however, must typically be supplemented by
additional data, as well as by clinically reasonable assumptions
where data are limited or nonexistent. As a result, decision
analysis methods are an obvious companion to systematic
reviews. However, when a systematic review is conducted, it is
unclear whether a decision model should be developed and used
in tandem with the systematic review and whether the decision
model results add value to the nature and strength of the evidence
summarized in the review. There is a lack of clarity about how to
simultaneously evaluate and present results from both the sys-
tematic review and the model. Prior work has raised (and in some
cases, addressed) important issues including 1) which input
estimates should be used as a result of a systematic review [4]
and 2) how to incorporate quality or strength of evidence into
decision models [5]. Thus, we conducted a study to help inform a
framework for deciding when and how a decision model and its
results should be added to a systematic review. As part of this
study, we collected information from all key stakeholders involved
in conducting and using systematic reviews in the United States:
1) the Evidence-Based Practice Centers (EPCs) as they are the
largest producers of systematic reviews; 2) the United States
Preventive Services Task Force (USPSTF), a key user of a large
number of systematic reviews; and 3) expert modelers.
Working in conjunction with the Agency for Healthcare
Research and Quality and a technical expert panel established
to provide guidance on all aspects of the study, we identified the
following main questions:equations that
simulates the
communicable
diseases, such as
1.interactions vaccinations
How and when have decision models been used alongside
systematic reviews?between
2.individuals and
How do key individuals who routinely perform systematic
reviews view the use and potential value of decision models?the spread of
3.disease
Discrete event Simulates time to EvaluatingWhat is the recent experience of the USPSTF, a key user of
systematic reviews, with respect to using decision models
alongside systematic reviews?simulation an event and alternative
4.model subsequent
events, one
health care
systems (e.g.,What were the experiences of the modeling teams who
developed decision models alongside the systematic reviews
used by the USPSTF?individual at a workflow,
5.time as well as
interactions
among
individuals or
within a health
care system
staffing) though
flexible enough
to address
questions in
several different
areasWhat can be learned from expert modelers frequently
involved in the development and use of decision models
alongside systematic reviews?
Prior to answering these questions, the concept of a ‘‘decision
model’’ needed to be defined. Decision models vary from very
simple ‘‘back of the envelope’’ calculations to complex computer-
based microsimulation and optimization. While the term ‘‘model’’
conveys different meanings in different clinical settings [6],
we followed the taxonomy developed by Brennan et al. [7] and
focused on decision-analytic model structures (Table 1). Decision-
analytic models are typically used in medical decision-making
applications: decision trees, Markov (cohort) models, microsimu-
lation (individual) models, dynamic models, and discrete event
simulation models.Methods
To answer the key questions and inform the development of a
framework, we used a mixed-method qualitative approach. First,
we summarized the use of decision models in all EPCs’ evidence
reports to identify when and why decision models were devel-
oped alongside systematic reviews. As noted earlier, EPCs are the
largest producers of systematic reviews in the United States.
Another literature review summarized current best practices forthe development of decision models. Next, we conducted a series
of elite interviews with three groups of key informants: EPC
directors and their staff, USPSTF members who participated in
recent recommendations based on the results from decision
models in addition to systematic reviews, and the corresponding
group of expert modelers who developed the models used by the
USPSTF. Last, a focus group of expert modelers offered views
regarding best practices for model development. We briefly
describe each of these methods below; the full report [8] provides
complete detail for the methods.
Literature Reviews
Use of decision models in evidence reports
To identify reports for which a decision model was developed
alongside a systematic review, we reviewed all 193 evidence
reports generated by the EPCs available, but not archived, on
the Agency for Healthcare Research and Quality EPC Evidence
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model’s use and purpose as well as the types of interventions and
conditions for which the models were developed. To ensure
completeness of this task, we also queried EPC staff to identify
any report that may have been missed. We analyzed reports to
derive any additional information that could inform a framework
for deciding how and when to use decision models alongside
systematic reviews.Best practices in decision modeling
A second systematic review identified articles that recommended
best practices for developing decision models. We used two
search strategies: 1) a keyword search algorithm designed to
locate both model and ‘‘best practices’’ constructs from database
inception to March 2010 and 2) an update of the search strategy
used by Philips et al. [10] for their review of good practice
guidelines. To complement the review, we also searched the gray
literature via Web search engines for published guidelines from
professional societies, governmental bodies, and other health-
related organizations. We reviewed articles and extracted infor-
mation that could further inform a framework for developing a
decision model alongside a systematic review.Key Informants Interviews
EPC directors and staff
To complement the review of EPC reports and to better under-
stand if, when, and why decision models are developed alongside
systematic reviews, we interviewed EPC directors and staff
members. We sought to 1) discuss whether and why EPCs have
been involved in decision modeling activities and whether the
modeling results were incorporated into reports; and 2) deter-
mine the factors instrumental in considering, developing, and
completing/abandoning modeling activities. We interviewed
members from all EPCs rather than only those EPCs that have
incorporated models because we wanted to incorporate lessons
and gather reasoning and perspectives from EPCs who 1) have
considered and attempted to incorporate modeling but decided
not to or 2) have not considered developing or incorporating
models at all or 3) have no familiarity with modeling.
We developed a semi-structured interview guide, identified 20
potential respondents, and conducted interviews from December
15, 2009, through March 2010, either by phone or face to face.
Interviews were recorded and analyzed.USPSTF and expert modelers
To evaluate strengths and weaknesses of current approaches to
jointly conducting a systematic review and modeling exercise, we
conducted key informant interviews with members of the
USPSTF and modeling groups involved with the recent colorectal
cancer, breast cancer, and cervical cancer modeling projects
[11–13]. The interviews were designed to 1) evaluate all stake-
holder experiences with the process including their perceived
needs and whether they were met, 2) understand the impact of
the modeling exercises on USPSTF decision making, and 3) make
recommendations for the process of conducting similar projects.
The final sample of respondents consisted of the leaders of the
three USPSTF cancer modeling projects, members of each mod-
eling team, and USPSTF members who were involved in either or
both the development of the models and voting on recommenda-
tions (the evidence for which included modeling). The interview
guide focused on strengths and weaknesses of current
approaches, perceived needs, degree to which needs are met,
lessons learned from the cancer screening modeling projects,
and perceived impact of these projects on USPSTF decisionmaking. Interviews lasted about an hour via telephone between
April 5, 2010, and May 25, 2010.
Expert Modeler Focus Group
We convened a focus group of expert modelers to discuss,
characterize, and qualify best practices in decision and simula-
tion modeling in the context of systematic reviews. Discussions
explored model development and construction, handling and
presentation of modeling assumptions, and presentation and
communication of results. Focus group participants included
expert modelers who work frequently with the United Kingdom
National Institute for Health and Clinical Excellence, an organi-
zation that uses decision or simulation modeling to provide
guidance to the National Health Service on the clinical effective-
ness and cost-effectiveness of selected medical technologies.
We provided participants with advance summaries of preliminary
findings from interviews with EPC members and with a selection
of articles on best practices. The focus group was conducted in
May 2010 and (with prior consent of participants) was recorded,
analyzed, and summarized.Results
The EPCs’ Perspective(s)
Evidence reports
Out of 192 evidence reports reviewed, 10 reports (5.2%) used
decision analysis. All but two developed new models as part of
the process. One evidence report [14] adapted a previously
published model while the second report [15] further refined
the model. Six reports modeled diagnostic tests or screening
strategies along with subsequent treatments [16–21], while three
reports modeled treatments only [14,15,22]. Only three reports
used models as the prime methodology to answer key questions
[14,15] or address the main research aim [18]. The remaining
seven reports used models to augment systematic review results
in cases where preliminary searches suggested that the literature
would be unable to address the key question directly.
The reason most often given for incorporating models into the
evidence reports was to provide a link between intermediate
outcomes and clinical, or patient-centered, outcomes. Other
reasons included simulating head-to-head comparisons other-
wise unavailable in the literature, examining cost-effectiveness,
and determining the effectiveness of screening under specific
scenarios by modeling a novel hypothesis for disease progression
not previously mentioned in the literature. The reports, however,
infrequently stated clear purposes for incorporating decision-
analytic models.
Models contributed to conclusions in several ways. Seven
evidence reports used model results to conclude more optimal
practices or no clinically important distinguishable differences
[12,13,16,17,19,20,22,23]. One model demonstrated that outputs
were sensitive to changes in key input variables and thus
contributed to concluding that the current evidence was insuffi-
cient to support broad implementation of the treatment [15].
Models that relied on low-quality evidence were reported as
exploratory [22]. Two modeling exercises were performed to
promote understanding of the interactions between the variables
of an analytic framework rather than to provide a basis for
clinical recommendations [18,20].
One evidence report described a modeling effort intended to
evaluate the usefulness of diagnostic modalities that differenti-
ate epileptic seizures from seizures commonly mistaken for
epilepsy [24]. The effort would have required diagnostic perfor-
mance data from multiple sources to accurately model the
Table 2 – Differences between responses of interviewees with and without modeling experience.
Interview theme Interviewees with experience (n ¼ 15) Interviewees without experience
(n ¼ 4)
Attitudes Toward Models and
Appropriateness of
Modeling in Systematic
Reviews
 Important set of techniques and strategies for
analysis and should be incorporated into sys-
tematic reviews
 Natural extension of the systematic review by
addressing gaps in the literature and extending
information about intermediate benefits and
harms to terminal outcomes
 Systematic review should be limited to synthesis
and meta-analysis of all available empirical and
observational evidence
 Models are outside the scope and purpose of the
systematic review
Research Questions and
Contexts Best Suited for
Decision and Simulation
Modeling
 Comparison of testing strategies (start, stop, and
interval)
 Determination of complicated net benefit calcu-
lations by linking intermediate to terminal ben-
efits and harms with additional data sources
 Questions with high degree of uncertainty
 Application of findings to subpopulations not
included in the original study
 Situations with high degree of uncertainty
 Difficulty enumerating, but agreed with the
‘‘with experience’’ examples when prompted
Definition of Decision and
Simulation Models
 Mathematical representation of a decision based
on empirical input parameters, supported by a
framework, and subject to a set of identifiable
assumptions
 Confusion on where modeling is defined differ-
ently from statistical inference
Evaluation of Models and
Assessment of Model
Outcomes
 Quality and expertise of the modeler(s)
 Lack of defined standards
 Inspection of assumptions and theoretical frame-
work (natural history of disease representation)
 Focus on the quality and ‘‘believability’’ of the
output parameters, and whether multiple mod-
els generated similar results
 Lacked familiarity with any empirical measures
of model quality
Decision and Simulation
Models Results as Evidence
 Outputs generated from models merit inclusion
in systematic reviews as evidence
 Modeling offers access to parameters that might
not otherwise be available (e.g., subpopulations)
 Model evidence is ‘‘manufactured’’ or ‘‘model
produced’’ and thus must be kept separate from
empirical evidence (RCT or observational)
 There is no evidence grading for model-based
parameters
Impact of Decision and
Simulation Modeling on
Systematic Reviews
 Models require additional time and expense, and
are not always able to be anticipated at the
initiation of a project
 Likely to add 20%–40% to the time and expense of
a typical systematic review
 Need a mechanism to include a model after the
question refinement phase has been completed!
 Would require expertise that some EPCs do not
have in-house, and thus must contract for
externally
 Need to have guidelines from the Methods
Manual
Training Needs
 Increase training opportunities for doctoral and
postdoctoral positions to train modelers
 Need for seminars and programs to train exist-
ing EPC staff
 Identify modeling groups with specific expertise
to contract with for model components of sys-
tematic reviews
EPC, Evidence-Based Practice Center; RCT, randomized controlled trial.
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ever, prevented the model from being developed.EPC directors and staff
Nineteen of the 20 EPC directors and designated staff contacted
were interviewed, representing 12 of the 13 EPCs (92.3%). Seven
main themes emerged from the discussions (Table 2). Most themes
were addressed across all EPC discussions, depending on the
interviewees’ experience with modeling. Of the 19 interviewees,
15 had either personal modeling experience/expertise or were
members of an EPC with modeling experience. Interviewees with
experience tended to respond more similarly than did those with-
out experience. Table 2 summarizes the key differences between
interviewees with and without modeling experience with respect
to the seven major themes that emerged from the interviews.
Interviewees with modeling experience were unanimously
positive about how models can augment the evidence from
systematic reviews. They stated that models are well suited to
address gaps in the literature and to synthesize literature from
differing sources and contexts into a single representation of theempirical evidence. They identified certain research questions as
lending themselves to modeling, including those regarding
screening as well as those involving harms or benefits measured
with intermediate outcomes instead of the terminal outcome of
interest, such as survival or disease prevention. They also noted
comparison of testing, prevention, and diagnostic strategies as
areas of great benefit for modeling. They pointed out that
decision models can best quantify net benefit (benefits less
harms). More generally, respondents viewed models as well
suited for research questions in which there is a high degree of
uncertainty in assumptions or input parameters, or in situations
in which there is a great amount of discordance between
estimates in empirical studies. They felt that models offer great
benefit over alternative methods (such as randomized controlled
trials or observational methods) to derive findings for small
specific subpopulations of interest. Last, they noted that models
are essential for determining the value of information as related
to future research priorities and directions. Interviewees identi-
fied the lack of defined standards and methods as a major
problem for evaluating models and presentation of outputs; they
expressed the need for a framework to fill this gap. Many
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need for a model and/or simulation in advance, specifically
before the completion of the question refinement phase or the
early stage literature review.
Interviewees without experience believed that developing a
model was beyond the scope of a systematic review of the
literature and questioned whether published models and related
output constitute valid information that could be included in
systematic reviews. They questioned incorporating and evaluating
the ‘‘engineered’’ evidence provided by such modeling studies.
While opinions differed regarding whether outputs of models
should be presented along with other evidence in systematic
reviews, both groups of interviewees recognized the lack of
standards and directions in grading and reporting such ‘‘evidence’’
and indicated that a framework should address such issues.
Users’ and modelers’ perspectives
Three main themes emerged from the interviews with cancer
modelers and USPSTF members about conducting decision and
simulation models alongside systematic reviews to inform
USPSTF recommendations: 1) communication and presentation
of model results, 2) modeling literacy, and 3) recommendations
for future projects. Although the modeling efforts were conducted
differently across the three cancer projects, interviewees expressed
consistent views about the difficulty of communicating model
results and the challenge of communicating model results, parti-
cularly to decision makers who were not knowledgeable about
modeling. They stressed that these issues must be addressed to
improve the success, acceptance, and use of models.
Respondents offered recommendations for future projects
along five basic categories: 1) goals and objectives for the project,
2) outputs and results, 3) USPSTF interactions with modelers and/
or reviewers, 4) project lead on the USPSTF, and 5) interactions
between modeling and systematic review teams.
USPSTF’s goals and objectives for the modeling effort must be
explicit and understood by both modelers and USPSTF leads.
Project members must identify the areas within each question
where modeling is anticipated to have the most impact and
benefit, so that modelers can tune the analysis accordingly.
Models have the greatest potential impact in determining the
start, stop, and interval for different testing strategies, an essen-
tial USPSTF objective. Furthermore, the USPSTF can use models
in key questions to assess the net benefit and magnitude of the
effect/benefit. Only when these goals and objectives are specific,
clear, and aligned, can the modeling effort deliver the necessary
results and associated impact. Lack of clarity has been a problem.
Modelers need to be very specific with USPSTF leads and the
systematic review team as to the key questions (or components
thereof) that modeling can likely impact, and whether the
evidence for a specific issue is sufficient to develop a valid model.
Outputs from a model must be designed in a purposeful and
careful manner. From a model user’s perspective (as opposed to a
modeler’s perspective), the ‘‘outputs are the model,’’ and as such,
outputs must be constructed to answer questions that inform
and support decision making. One interviewee suggested that
designing tables and figures before the start of the project would
clarify goals and expectations while ensuring results of value for
decision making. According to this thinking, not only should the
modeling effort confirm an existing conclusion, but its outputs
should also be directly usable by decision makers to inform
and aid in the specific decision or recommendation of interest.
Some respondents expressed concern that modeling efforts
provide too much or too little information, and in some cases, fail
to provide the information that decision makers need, thus
leaving them to interpret or interpolate the results to address
the recommendations.Modelers prefer an iterative process that allows interim read-
outs of results with the USPSTF lead. One modeler commented
that an ‘‘iterative process is a much better discipline for mode-
lers, especially with complex questions y interaction with the
lead would have served us well, and allowed us to develop a
better model.’’ Unclear communication could result in modeling
results that are less informative and require additional analyses.
Such an iterative process will ‘‘give the task force members, or at
least the lead, more confidence in the model and a better ability
to accurately use and communicate the model results.’’
Two of the three projects reviewed mentioned that informed,
model-literate leadership within the USPSTF was an essential
component of success. In both cases, the modelers and the
USPSTF lead reported a modeling project that impacted the
USPSTF recommendations and allowed the task force to make
either a ‘‘more detailed recommendation’’ or ‘‘to increase the
certainty and/or the magnitude of the effects.’’ Modelers noted
that these USPSTF leads were familiar with models and had used
them in their professional experiences, and thus were able to ‘‘be
much more specific and answer detailed questions about their
request y also they were able to challenge us on some of our
logic.’’
Many recommendations emerged from interactions among
modeling groups and with systematic review teams. Interviewees
consistently cited the Cancer Intervention and Surveillance
Modeling Network structure and operations as an example of
best practice for interactions among modeling teams. They saw
the operations of the Cancer Intervention and Surveillance
Modeling Network as providing the right balance between fre-
quent interactions and collaboration among the modeling teams
and the need to maintain distinct and separate models demon-
strating disparate representations of the disease. They also saw
the Cancer Intervention and Surveillance Modeling Network
structure as an advantage for building repositories of expertise
in specific diseases.
Best Practices
Literature review
Of the 39 articles that provided guidance on what constitutes
a good decision model, 7 discuss good modeling practices;
4 discuss the roles, uses, or value of modeling in general; 20
focus on specific aspects of modeling; 3 propose comprehensive
guidelines for modeling in a specific clinical domain; and 5
review and compare models in specific clinical areas. Although
the guidance for model users is extensive and fairly consistent, it
can be vague. For example, model structure is recognized as
important, yet we have no explicit guidelines for how to judge
this. Furthermore, existing guidance focuses on the technical
aspects of models, not the process or expertise required to
conduct a modeling study. Nor does guidance address how best
to illustrate and present models and modeling results or develop
capacity to understand decision models and overcome the black
box problem. In addition, modeling guidelines focus primarily on
Markov models and less often on other types such as dynamic or
discrete event models. Nor does much guidance exist for the
optimal approach to choosing the type of model for a particular
problem.
Modelers face many challenges as they seek to assist decision
makers and improve the quality of decision making. In the
context of medical tests, Trikalinos et al. [25] summarize these
challenges and the various situations in which they surface. The
challenges include 1) insufficient data on key input quantities
(such as prevalence, test performance, and effectiveness); 2) the
potential nontransferability of performance across studies; 3) the
choice of modeling outcomes (e.g., event-free survival, survival,
and quality-adjusted life-years); 4) the methods for meta-
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of complex models. This list echoes Tavakoli et al. [26], who also
emphasize the task of identifying data as a major difficulty in
developing decision models, specifically 1) epidemiological data
on the risk of subsequent outcomes, 2) effectiveness data essen-
tial to estimate treatment benefits and harms as well as the
probabilities of various outcomes given specific decisions over
clinical pathways, and 3) health state valuation data necessary
to estimate the utilities to be attached to specific outcomes.
By definition, models are simplified representations of a real
problem; thus, they are incomplete and inherently limited. They
are useful, however, precisely for that reason. They promote
transparency by pinpointing the influential constituents of each
problem and by providing systematic uncertainty analysis to fully
appreciate the impact of parameter estimates. To capitalize on the
potential value of models, it is necessary to clearly identify and
communicate their assumptions, challenges, and limitations.Expert modeler focus group
Focus group experts structured the discussion of modeling within
the context of a decision-making framework. They reiterated the
results from the literature review regarding the quality of models,
they further developed the need for interaction between the
model and the decision maker(s) the model is intended to inform,
and they elaborated on the importance of communicating the
model and its results. The focus group described an essential
need to discuss modeling within the proper context of a decision-
making framework. They stressed that this clarifies the model-
ing’s main goal: To generate an unbiased synthesis of available
evidence on the basis of clearly stated assumptions, and thus to
produce information not otherwise available to support, not make,
the decisions of individual(s) who must present complex but
well-defined recommendations. The focus group noted that most
individuals tasked with complex decisions, such as members of
the USPSTF, value both the availability of a decision analytic
framework and help from decision models. In the view of the
focus group, the main issues regarding the acceptance of models
and their results generally stem from stakeholders and broader
communities who may or may not welcome or accept the
resulting decision and/or recommendations.
The focus group identified the interface between the model
and the decision maker as a neglected aspect of best practice for
conducting models alongside systematic reviews. They discussed
four key issues: 1) nature of evidence produced by models,
2) nature and extent of a decision maker’s involvement in the
modeling effort, 3) transparency versus trust in the model, and
4) communication and visualization.
Not surprisingly, expert modelers agreed that models consti-
tute ‘‘inferential’’ or ‘‘carefully manufactured’’ evidence not
otherwise available and that models need to be incorporated
along with other evidence generated through systematic reviews.
The nature of the evidence generated may differ and require
viewing through different lenses, but it provides otherwise
inaccessible information to support decisions. Furthermore, one
could argue that an implicit ‘‘mental model’’ is applied in
reviewing and evaluating evidence in systematic reviews and
that this mental model should also be made more explicit.
One problem related to the acceptance (and therefore the use
and usefulness) of models is that models are first developed by a
technical team that passes on the results to decision makers
without interacting with them in advance of and during the
process. This practice may be ineffective and lead to the wrong
model being developed, misunderstanding of the model and its
results, and low acceptance and use. In a framework of decision
support, the development of a model should be a multidisciplin-
ary effort involving clinical experts, modeling experts, anddecision makers from inception to completion of the project. A
modeling report generally has multiple audiences and therefore
the model and its results must be carefully explained and
understood by the relevant stakeholders. Structured interaction
and involvement between decision makers and the modeling
team would greatly enhance the understanding, acceptance, and
use of models.
Respondents perceived transparency as somewhat of a para-
dox. Transparency is essential if peer expert modelers are to
review and evaluate models; however, stakeholders generally do
not want transparency despite their stated wish for it. Rather,
stakeholders want to ‘‘trust’’ models. Because the majority of
stakeholders and users are unfamiliar with modeling, transpar-
ency into the intricacies of a model offers little value and may
even detract from building trust and acceptance. The ultimate
test of how good a model is resides in its usefulness, its actual
use, and the degree to which stakeholders understand and accept
the model outputs. Increased public acceptance of models and
their results will hinge on the contribution of individuals who can
clearly and simply explain to lay audiences what a model is and
does. Focus group members offered no specific recommendations
on how to find or train such individuals, but they did stress the
importance of building such expertise.Conclusions
We used a variety of approaches to address important issues
regarding the development and use of decision models alongside
systematic reviews. We aimed to generate useful information for
developing a framework for determining if and when a decision-
analytic model might add value to a systematic review, and how
to best accomplish such an endeavor. Overall, the results demon-
strated that models are well suited to address gaps in the
literature, better suited for certain types of research questions,
and essential for determining the value of information relating to
future research. While opinions differed regarding whether
model outputs constitute evidence, interviewees expressed con-
cern over the lack of standards and directions in grading and
reporting such ‘‘evidence.’’ Interviews of stakeholders and mode-
lers revealed the importance of communication and presentation
of model results as well as the importance of model literacy and
involvement of decision makers. We organized the information
that emerged from our inquiries into a proposed framework as
described in the full report [8].Acknowledgments
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